Key highlights
- Confirmed objective response rate increased to 12.5 percent from a previous 8.3 percent
- Clinical study evaluated 24 patients using RANO 2.0 criteria for intranasal NEO100
- FDA Type B End-of-Phase meeting scheduled for January 2027 to discuss Phase 3 trial design
- CEO Amir Heshmatpour purchased 30,000 additional shares on the open market in November
- Year-to-date insider buying by the CEO totals 371,000 shares valued at over $1.5 million
Clinical Trial Advancements
NeOnc Technologies reported updated interim results from its Phase 2a clinical study of intranasal NEO100, a drug candidate targeting malignant brain tumors. The latest analysis confirms an additional patient response, bringing the total to 3 out of 24 participants. This adjustment increases the objective response rate to 12.5 percent, up from the previously reported 8.3 percent. Responses were assessed using the Response Assessment in Neuro-Oncology 2.0 criteria. This update follows the initial topline results released in August 2026 and represents a continuing evaluation of the therapy's efficacy in high-need oncology segments.
Regulatory and Strategic Milestones
- Type B End-of-Phase meeting with the FDA scheduled for early January 2027
- Discussions to focus on potential accelerated approval pathways for NEO100
- Planned presentation of Phase 3 confirmatory trial design to federal regulators
- Advancement of oral candidate NEO212 toward Phase 2 clinical development
- Maintenance of exclusive worldwide licensing for University of Southern California patents
Executive Conviction
“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer.”
Financial and Market Position
NeOnc Technologies currently maintains a market capitalization of approximately 129.3 million dollars. The company's stock has demonstrated significant short-term momentum, recording a 64.7 percent increase over the past month. Insider activity has remained robust, with CEO Amir Heshmatpour acquiring 291,000 shares since the August trial data release. These open-market purchases were conducted using personal funds and did not involve the issuance of new equity. The company remains focused on its CNS cancer pipeline while operating with a technical RSI of 64.8, reflecting a period of increased investor attention.
Management commentary
“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer.”
| Share price | $4.48 |
|---|---|
| Market cap | $129M |
| Revenue (annual) | $39,990 |
| 1-month price change | +64.71% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by NeOnc Technologies Holdings, Inc. announcing updated clinical trial data and insider share purchases.
Track NEONC TECHNOLOGIES HOLDINGS, INC. live
Get the next NEONC TECHNOLOGIES HOLDINGS, INC. SEC filing seconds after it lands.